Interestingly, pharmacological activation of AMPK by 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin, the mTORC1 inhibitor, to kill human cancer cells by regulating phospholipase D (PLD) activity [21]. Here, PRKAA2 is linked to cancer.